Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

MorphoSys And Novozymes Sign Long-Term Alliance On Slonomics Technology

MorphoSys AG (MPSYY.PK) and Novozymes A/S Thursday said they have signed a multi-year licensing and technology transfer agreement. The agreement provides Novozymes with a non-exclusive license to use MorphoSys's proprietary Slonomics technology to develop novel products within the industrial biotechnology sector.

Novozymes becomes the first industrial biotech company to have access to Slonomics technology. Financial details were not disclosed.

Slonomics technology, which comprises patented methods and know-how, advanced materials and robotic equipment, allows combination of building blocks in exactly the preferred order and composition. Researchers can thus create only the desired diversity among a set of enzyme variants, eliminating all the undesired combinations. In a typical scenario, Novozymes' researchers can reduce the number of variants made from millions to ten thousand.

Click here to receive FREE breaking news email alerts for MorphoSys AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Germany consumer confidence is set to improve further in August to the strongest level since December 2006 despite escalating geopolitical tensions in Israel and Ukraine, data from market research group GfK showed Friday. The forward-looking consumer sentiment index rose to 9 in August, while it was expected to remain unchanged at 8.9. This was the highest value recorded since December 2006. Amazon.com, Inc. said Thursday that its second quarter loss widened from last year, as operating expenses outpaced revenue growth amid heavy spending on new technology and contents. The company's quarterly loss per share was also wider than what analysts expected, but is quarterly sales came in line with analysts' forecast. The company also forecast an operating loss for the current quarter. After failing to sustain an initial upward move, stocks showed a lack of direction throughout much of the trading day on Thursday. The major averages eventually closed nearly unchanged, turning in a mixed performance for the second straight day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.